Caspofungin

Restricted
C difficile risk
Low
Oral Bioavailability
N/A

Spectrum Of Activity

Dosing

Infants <3 months (Limited data available):

  • IV: 25 mg/m² once daily --- contact Infectious Diseases and Pharmacy for specific dosing considerations.

Infants ≥3 months, Children, and Adolescents <18 years:

  • IV: Initial 70 mg/m² on day 1, then 50 mg/m² once daily starting on day 2; may increase to 70 mg/m² once daily if clinical response inadequate; maximum dose: 70 mg/dose.

Infants <3 months:

  • No data available - Contact Infectious Diseases and Pharmacy for specific dosing considerations.

Infants ≥3 months, Children, and Adolescents <18 years:

  • IV: Initial 70 mg/m² on day 1, then 50 mg/m² once daily starting on day 2; may increase to 70 mg/m² once daily if clinical response inadequate; maximum dose: 70 mg/dose.

Infants <3 months: Limited data available: IV: 25 mg/m² once daily

  • Contact Infectious Diseases and Pharmacy for specific dosing considerations.

  • There is a recommended dose reduction in patients with moderate hepatic insufficiency however this is largely based upon adult data.

  • Contact Infectious Diseases service or clinical pharmacist for further evaluation.

No adjustment necessary

This antimicrobial is restricted to Infectious Diseases

General Information

Caspofungin is often used in management of suspected and confirmed invasive fungal infections, particularly Candidiasis and Aspergillosis

  • Liver enzymes at baseline and every 1-2 weeks

  • Infusion-related reactions (rash, pruritis)

  • Phlebitis

  • Headache

  • Nausea and vomiting

  • Elevations in hepatic enzymes

Caspofungin has poor vitreous, CNS and urinary penetration. It should not be used for treatment of Candida urinary tract infections.

Use must be approved by Infectious Diseases.

Antimicrobial class: Echinocandin

Biliary penetration: Therapeutic

CSF penetration: Poor

Lung penetration: Therapeutic

Urine penetration: Poor